Previous studies have shown that miR-143 targets oncogenic pathways such as ERK/MAPK, PI3K/AKT, and androgen receptor signaling, all of which contribute to prostate cancer progression and drug resistance (27, 28). This evidence concerns the gene AKT1 and prostate carcinoma.